drugset / Trial / NCT04227041

A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

NCT04227041

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.

Timeline

Start
2020-01-10
Primary completion
2021-01-10
Completion
2023-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject Pyrotinib Small molecule

Indications